Búsqueda | Portal de Búsqueda de la BVS España

1.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Gore, M E; Szczylik, C; Porta, C; Bracarda, S; Bjarnason, G A; Oudard, S; Lee, S-H; Haanen, J; Castellano, D; Vrdoljak, E; Schöffski, P; Mainwaring, P; Hawkins, R E; Crinò, L; Kim, T M; Carteni, G; Eberhardt, W E E; Zhang, K; Fly, K; Matczak, E; Lechuga, M J; Hariharan, S; Bukowski, R.

Br J Cancer; 113(1): 12-9, 2015 Jun 30.

Artículo en Inglés | MEDLINE | ID: mdl-26086878

2.

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.

White, N M A; Masui, O; Newsted, D; Scorilas, A; Romaschin, A D; Bjarnason, G A; Siu, K W M; Yousef, G M.

Br J Cancer; 110(5): 1250-9, 2014 Mar 04.

Artículo en Inglés | MEDLINE | ID: mdl-24496460

3.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

Jonker, D J; Karapetis, C S; Harbison, C; O'Callaghan, C J; Tu, D; Simes, R J; Malone, D P; Langer, C; Tebbutt, N; Price, T J; Shapiro, J; Siu, L L; Wong, R P W; Bjarnason, G; Moore, M J; Zalcberg, J R; Khambata-Ford, S.

Br J Cancer; 110(3): 648-55, 2014 Feb 04.

Artículo en Inglés | MEDLINE | ID: mdl-24335920

4.

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

Ko, J J; Choueiri, T K; Rini, B I; Lee, J-L; Kroeger, N; Srinivas, S; Harshman, L C; Knox, J J; Bjarnason, G A; MacKenzie, M J; Wood, L; Vaishampayan, U N; Agarwal, N; Pal, S K; Tan, M-H; Rha, S Y; Yuasa, T; Donskov, F; Bamias, A; Heng, D Y C.

Br J Cancer; 110(8): 1917-22, 2014 Apr 15.

Artículo en Inglés | MEDLINE | ID: mdl-24691425

5.

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

Heng, D Y C; Choueiri, T K; Rini, B I; Lee, J; Yuasa, T; Pal, S K; Srinivas, S; Bjarnason, G A; Knox, J J; Mackenzie, M; Vaishampayan, U N; Tan, M H; Rha, S Y; Donskov, F; Agarwal, N; Kollmannsberger, C; North, S; Wood, L A.

Ann Oncol; 25(1): 149-54, 2014 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-24356626

6.

miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma.

Khella, H W Z; Bakhet, M; Allo, G; Jewett, M A S; Girgis, A H; Latif, A; Girgis, H; Von Both, I; Bjarnason, G A; Yousef, G M.

Carcinogenesis; 34(10): 2231-9, 2013 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-23715501

7.

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.

White, N M A; Masui, O; Newsted, D; Scorilas, A; Romaschin, A D; Bjarnason, G A; Siu, K W M; Yousef, G M.

Br J Cancer; 116(6): e3, 2017 03 14.

Artículo en Inglés | MEDLINE | ID: mdl-28081542

8.

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

Heng, D Y; Mackenzie, M J; Vaishampayan, U N; Bjarnason, G A; Knox, J J; Tan, M H; Wood, L; Wang, Y; Kollmannsberger, C; North, S; Donskov, F; Rini, B I; Choueiri, T K.

Ann Oncol; 23(6): 1549-55, 2012 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-22056973

9.

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

Giacchetti, S; Dugué, P A; Innominato, P F; Bjarnason, G A; Focan, C; Garufi, C; Tumolo, S; Coudert, B; Iacobelli, S; Smaaland, R; Tampellini, M; Adam, R; Moreau, T; Lévi, F.

Ann Oncol; 23(12): 3110-3116, 2012 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-22745214

10.

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215.

White, N M A; Khella, H W Z; Grigull, J; Adzovic, S; Youssef, Y M; Honey, R J; Stewart, R; Pace, K T; Bjarnason, G A; Jewett, M A S; Evans, A J; Gabril, M; Yousef, G M.

Br J Cancer; 105(11): 1741-9, 2011 Nov 22.

Artículo en Inglés | MEDLINE | ID: mdl-22033272

11.

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.

MacKenzie, M J; Rini, B I; Elson, P; Schwandt, A; Wood, L; Trinkhaus, M; Bjarnason, G; Knox, J.

Ann Oncol; 22(1): 145-148, 2011 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-20595449

12.

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Stukalin, I; Wells, J C; Graham, J; Yuasa, T; Beuselinck, B; Kollmansberger, C; Ernst, D S; Agarwal, N; Le, T; Donskov, F; Hansen, A R; Bjarnason, G A; Srinivas, S; Wood, L A; Alva, A S; Kanesvaran, R; Fu, S Y F; Davis, I D; Choueiri, T K; Heng, D Y C.

Curr Oncol; 26(2): e175-e179, 2019 04.

Artículo en Inglés | MEDLINE | ID: mdl-31043824

13.

Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.

Nazha, Sara; Tanguay, Simon; Kapoor, Anil; Jewett, Michael; Kollmannsberger, Christian; Wood, Lori; Bjarnason, G A Georg; Heng, Daniel; Soulières, Denis; Reaume, Martin Neil; Basappa, Naveen; Lévesque, Eric; Dragomir, Alice.

Clin Drug Investig; 38(12): 1155-1165, 2018 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-30267257

14.

Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Nazha, S; Tanguay, S; Kapoor, A; Jewett, M; Kollmannsberger, C; Wood, L; Bjarnason, G; Heng, D; Soulières, D; Reaume, N; Basappa, N; Lévesque, E; Dragomir, A.

Curr Oncol; 25(6): e576-e584, 2018 12.

Artículo en Inglés | MEDLINE | ID: mdl-30607126

15.

Does the Time of Radiotherapy Affect Treatment Outcomes? A Review of the Literature.

Chan, S; Rowbottom, L; McDonald, R; Bjarnason, G A; Tsao, M; Danjoux, C; Barnes, E; Popovic, M; Lam, H; DeAngelis, C; Chow, E.

Clin Oncol (R Coll Radiol); 29(4): 231-238, 2017 04.

Artículo en Inglés | MEDLINE | ID: mdl-28034487

16.

Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.

Erlichman, C; Moore, M; Thiessen, J J; Kerr, I G; Walker, S; Goodman, P; Bjarnason, G; DeAngelis, C; Bunting, P.

Cancer Res; 53(20): 4837-42, 1993 Oct 15.

Artículo en Inglés | MEDLINE | ID: mdl-8402670

17.

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.

Maroun, J; Kocha, W; Kvols, L; Bjarnason, G; Chen, E; Germond, C; Hanna, S; Poitras, P; Rayson, D; Reid, R; Rivera, J; Roy, A; Shah, A; Sideris, L; Siu, L; Wong, R.

Curr Oncol; 13(2): 67-76, 2006 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-17576444

18.

Circadian cancer therapy.

Hrushesky, W J; Bjarnason, G A.

J Clin Oncol; 11(7): 1403-17, 1993 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-8315438

19.

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Townsley, C A; Chi, K; Ernst, D S; Belanger, K; Tannock, I; Bjarnason, G A; Stewart, D; Goel, R; Ruether, J D; Siu, L L; Jolivet, J; McIntosh, L; Seymour, L; Moore, M J.

J Clin Oncol; 21(8): 1524-9, 2003 Apr 15.

Artículo en Inglés | MEDLINE | ID: mdl-12697876

20.

Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.

Bjarnason, G A; Kerr, I G; Doyle, N; Macdonald, M; Sone, M.

Cancer Chemother Pharmacol; 33(3): 221-8, 1993.

Artículo en Inglés | MEDLINE | ID: mdl-8269603

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.

miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma.

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis.

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215.

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.

Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence.

Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Does the Time of Radiotherapy Affect Treatment Outcomes? A Review of the Literature.

Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.

Circadian cancer therapy.

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.